The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports

Biopharma Co. Adds CTO to Team

Research Report
  ()
This newest member brings with him extensive experience in protein development and manufacturing, noted an Oppenheimer report.
Tags:  Biotechnology / Pharmaceuticals

Trial Results Validate New Drug-Delivering Nasal Implant

Research Report
  ()
This product candidate presents a compelling approach to treating post-surgery chronic rhinosinusitis patients, noted an H.C. Wainwright & Co. report.
Tags:  Biotechnology / Pharmaceuticals

Co. Reaches Major Milestone With Novel Drug

Research Report
  ()
The biopharma initiated enrollment of a targeted 420 patients for one of its Phase 3 clinical trials evaluating its new cardiac myosin inhibitor, noted an H.C. Wainwright & Co. report.
Tags:  Biotechnology / Pharmaceuticals

After Seeing 86% Success Rate in Phase 2, Biotech Co. Moves to Phase 3 for AUD Treatment

  ()
Awakn Life Sciences has applied for Phase 3 of clinical trials after the success of Phase 2. Read on to see what this company plans for its flagship new drug.
Tags:  Biotechnology / Pharmaceuticals

FTC Settles Suit, Potentially Averting Further Hurdles

Contributed Opinion
  ()
McAlinden Research shares a deep dive into a market driver with alpha-generating potential.
Tags:  Biotechnology / Pharmaceuticals

New Vaccine for Chikungunya Shown To Be Safe in Youths

Research Report
  ()
The company behind the vaccine plans to use the safety data to support approvals in the U.S., European Union and Brazil, noted an H.C. Wainwright & Co. report.
Tags:  Biotechnology / Pharmaceuticals

Approved Drug for Skin Condition Shown Safe at Higher Dose

Research Report
  ()
Based on these positive Phase 1 trial results in actinic keratosis, the biopharma developer will seek label expansion in the U.S., noted a ROTH Capital Partners report.
Tags:  Biotechnology / Pharmaceuticals

Canadian Veterinary Co. Revenue Increased to CA$12.7 Million in First Half of 2023

  ()
Grey Wolf Animal Health Corp. has announced the financial results of the last quarter. Read on to see why one newsletter writer believes this stock is worth looking into.
Tags:  Biotechnology / Pharmaceuticals

Catalyst Rich 12 Months Ahead for U.S. Biopharma Co.

Research Report
  ()
Investors can expect to see new drug application filings, a PDUFA meeting outcome, clinical trial results and revenue stream additions, noted a ROTH Capital Partners report.
Tags:  Biotechnology / Pharmaceuticals

DNA Tech Co. Launches MRNA Platform and Files Two Patents

  ()
This company has announced the general availability of its Linea IVT platform evaluation kits and the first kit shipment to an existing Linea IVT Template customer. It has also filed two provisional patent applications for its technologies to reduce the impurities and decrease manufacturing costs for mRNA therapies like some COVID-19 vaccines. Read to see what experts are saying about the stock.
Tags:  Life Sciences Tools & DiagnosticsBiotechnology / Pharmaceuticals

FDA Approves New Oncology Drug for Clinical Trials

Research Report
  ()
The first in-human trial of this investigative small molecule is expected to start in Q4/23, noted a Wedbush report.
Tags:  Biotechnology / Pharmaceuticals

The Bond Market Has the Blues, Oil Breaks to the Upside and Moderna to the Downside

Contributed Opinion
  ()
The long end of the bond market is starting to price in sticky inflation, and Ron Struthers of Struthers' Stock Reports expects interest rates to rise further. Higher energy prices will start adding to inflation again, adding to the problem. Moderna has broken down on the chart and will be reporting red ink in the next few years. Time to go short.
Tags:  Oil & Gas - Exploration & ProductionBiotechnology / Pharmaceuticals

Biotech Co. An Attractive Investment

Contributed Opinion
  ()
Technical Analyst Clive Maund reviews Awakn Life Sciences Corp.'s 26-month and year-to-date charts to tell you why he believes it is an attractive investment.
Tags:  Biotechnology / Pharmaceuticals

Second Half of 2023 Is Catalyst Rich for This Biopharma Co.

Research Report
  ()
The firm continues advancing its lead drug candidates, including those for anxiety and treatment-resistant depression, noted an H.C. Wainwright & Co. report.
Tags:  PsychedelicsBiotechnology / Pharmaceuticals

Approval Sought in Japan for New SARS-CoV-2 Vaccine

Research Report
  ()
The vaccine developer's partner in Japan is already working on getting a manufacturing facility built there, noted an H.C. Wainwright & Co. report.
Tags:  Biotechnology / Pharmaceuticals

Co. Addresses Opioid Crisis Through Novel Platforms

Research Report
  ()
This California biotech, developing products that prevent opioid abuse and overdose, gained coverage by an H.C. Wainwright & Co. analyst, an initiation report noted.
Tags:  Biotechnology / Pharmaceuticals

New Psoriasis Drug Shown More Effective Than On-Market One

Research Report
  ()
Recent clinical trial results show the oral interleukin-23 receptor to be a "cleaner" target than non-receptor tyrosine kinase 2, noted a BTIG report.
Tags:  Biotechnology / Pharmaceuticals

Co. With Alzheimer's App 'Meaningfully Undervalued,' Analyst Says

Research Report
  ()
Despite having revenues below expectations, one analyst says this health company's Alzheimer's dementia diagnosis app is gaining commercial traction.
Tags:  Life Sciences Tools & DiagnosticsTechnologyHealthcare ServicesBiotechnology / Pharmaceuticals

Biotech Co. Remains Opportunity for Those With High Risk Tolerance

Research Report
  ()
Recently, Antibe Therapeutics released its fiscal 2023 year-end (FQ423) results, which remained inline with expectations, noted an Echelon Capital research note.
Tags:  Biotechnology / Pharmaceuticals

Q3: Chen Is Still Bullish on This Precious Metal

  ()
Asset manager Chen Lin continues to rely heavily on this precious metal. Find out his top picks for the third quarter of 2023.
Tags:  SilverBiotechnology / PharmaceuticalsOil & Gas - Exploration & Production

New Drug for Bone Growth Disorder Improves Height Velocity

Research Report
  ()
Phase 2 trial data at six months are positive in children with achondroplasia, noted a BTIG report.
Tags:  Biotechnology / Pharmaceuticals

Biotech Co. Completes Step Toward Psychedelic Treatment for Brain Injuries

  ()
Algernon Neuro has completed the third stage of its dosage trial for DMT as a treatment for traumatic brain injury. Read on to see how the company expects to take psychedelics into the mainstream.
Tags:  PsychedelicsBiotechnology / Pharmaceuticals

777% Gain Implied in Analyst's Target Price on Biopharma Co.

Research Report
  ()
Results from a Phase 2 trial of this U.S. company's cystic fibrosis drug are due out next month, noted an H.C. Wainwright & Co. report.
Tags:  Biotechnology / Pharmaceuticals

Biotech Co. To Exit Health Care Services

  ()
Friday, Awakn Life Sciences Corp. announced it would be taking focus away from healthcare services and instead concentrate its efforts exclusively on research and development for therapeutics for addiction treatment. Read more to learn what the global addiction treatment market looks like and where the company is headed in the future.
Tags:  Biotechnology / Pharmaceuticals

Key Catalyst for US Biopharma Stock on Track for Q4/23

Research Report
  ()
Readout of a Phase 2b trial is expected then, and positive data could support approval of the company's drug candidate, noted an H.C. Wainwright & Co. report.
Tags:  Biotechnology / Pharmaceuticals

Showing Results: 1 to 25 of 46 Next